Stock Markets March 5, 2026

Reckitt Surpasses Q4 Like-for-Like Sales Estimates as Emerging Markets Drive Growth

Consumer goods group finalised $4.8bn sale of Essential Home while keeping a 30% stake and forecasts 4-5% core growth for 2026

By Nina Shah RKT
Reckitt Surpasses Q4 Like-for-Like Sales Estimates as Emerging Markets Drive Growth
RKT

Reckitt reported fourth-quarter like-for-like net sales growth above company-compiled expectations, propelled by robust demand in emerging markets. The consumer goods maker completed the $4.8 billion divestment of its Essential Home division to Advent International on December 31 while retaining a 30% equity interest, and it is projecting core business growth of 4% to 5% in 2026. Management cautioned that Europe remains a weak trading environment and that seasonal over-the-counter sales could be affected by a milder cold and flu season in the first quarter of 2026.

Key Points

  • Reckitt reported 5.4% like-for-like net revenue growth for Q4, beating a company-compiled consensus expectation of 4.7%.
  • Emerging market revenues rose 14.6% for the year and now account for about 42% of Reckitt's core net revenues, delivering 10 consecutive quarters of double-digit growth per Barclays analysts.
  • Reckitt finalised the $4.8 billion sale of its Essential Home division to Advent International on December 31 and retained a 30% equity stake; the company forecasts 4-5% core business growth in 2026.

Reckitt reported better-than-expected like-for-like net sales growth for the fourth quarter ended December 31, citing particularly strong performance in emerging markets and reaffirming a medium-term growth target for its core businesses. The company said it expects its core operations to expand by 4% to 5% in 2026.

The maker of Durex condoms and Lysol cleaning products has been reshaping its portfolio alongside peers such as Nestle and Unilever, concentrating on higher-growth and higher-margin brands. As part of that strategy, Reckitt completed the divestment of its Essential Home division to private equity firm Advent International on December 31 for $4.8 billion, while retaining a 30% equity stake in the business.

For the quarter, group like-for-like net revenue rose 5.4%, ahead of a company-compiled consensus expectation of 4.7%.

Looking at full-year regional performance, emerging market revenue growth was a standout at 14.6%, while Europe recorded a decline of 1.4%. Emerging markets now represent roughly 42% of Reckitt's core net revenues and have delivered what Barclays analysts characterised as 10 consecutive quarters of double-digit sales growth.

Barclays analysts noted that emerging markets "is doing the heavy lifting for the group and provides a reliable growth engine at a time when developed markets category growth is sluggish."

Despite the stronger overall top-line, Reckitt signalled that headwinds persist in developed markets. The company said it expects the difficult trading backdrop in Europe to continue and warned that its seasonal over-the-counter (OTC) business could face a weaker first quarter of 2026 due to a milder cold and flu season.


The company update also appears alongside marketing material referenced to investor tools. One such reference asks whether investors should be buying RKT right now and describes a proprietary ProPicks AI tool that evaluates RKT alongside thousands of other companies each month using more than 100 financial metrics. That description states the AI searches for investments based on fundamentals, momentum, and valuation, and cites past notable winners including Super Micro Computer (+185%) and AppLovin (+157%). The promotional description notes the AI aims to identify stocks with attractive risk-reward profiles based on current data.

Reckitt's quarterly results underline the contrast between fast-growing emerging markets and softer demand in parts of the developed world. Management's guidance for 2026 points to modest core expansion, while the retained stake in Essential Home keeps some exposure to the divested business.

Risks

  • Ongoing weakness in the European trading environment could pressure overall sales and margins - impacting consumer goods and retail sectors.
  • A milder cold and flu season could reduce seasonal over-the-counter demand in Q1 2026, affecting healthcare and consumer healthcare product sales.

More from Stock Markets

Boskalis posts record 2025 EBITDA but flags weaker 2026 outlook Mar 5, 2026 Hunting Keeps 2026 Targets Intact as Order Book Shrinks Mar 5, 2026 Babcock Posts Small Earnings Beat and Unveils £75 Million Buyback Mar 5, 2026 Cicor posts sales above estimates as acquisitions weigh on margins Mar 5, 2026 R&S Group Tops Second-Half Profit Estimates and Reaffirms Medium-Term Targets Mar 5, 2026